STOCK TITAN
  1. Home
  2. Sec-filings
  3. TBPH
  4. [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Farnum Rhonda reported acquisition or exercise transactions in this Form 4 filing.

Theravance Biopharma, Inc. reported that SVP, Commercial & Medical Affairs Rhonda Farnum received a grant of 18,750 Ordinary Shares of the company on April 1, 2026. The shares were granted at a stated price of $0.00 per share as compensation rather than a market purchase.

Following this award, Farnum directly holds a total of 251,449 Ordinary Shares of Theravance Biopharma, Inc., reflecting an increase in her equity-based compensation stake in the company.

Positive

  • None.

Negative

  • None.
Insider Farnum Rhonda
Role SVP, COMM & MEDICAL AFFAIRS
Type Security Shares Price Value
Grant/Award Ordinary Shares 18,750 $0.00 --
Holdings After Transaction: Ordinary Shares — 251,449 shares (Direct)
Footnotes (1)
Shares granted 18,750 Ordinary Shares Equity grant to SVP Rhonda Farnum on April 1, 2026
Grant price per share $0.00 per share Stated transaction price for awarded Ordinary Shares
Total shares after transaction 251,449 Ordinary Shares Rhonda Farnum’s direct holdings following the award
Number of acquisition transactions 1 transaction Single grant, award, or other acquisition reported
Ordinary Shares financial
"security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farnum Rhonda
(Last)(First)(Middle)
C/O THERAVANCE BIOPHARMA US, LLC
901 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, COMM & MEDICAL AFFAIRS
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/01/2026A18,750A$0251,449D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Brett A Grimaud, Attorney-in-Fact04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Theravance Biopharma (TBPH) report for Rhonda Farnum?

Theravance Biopharma reported that SVP Rhonda Farnum received a grant of 18,750 Ordinary Shares. This award is classified as a “grant, award, or other acquisition,” indicating equity compensation rather than an open-market purchase or sale, and increases her direct share ownership in the company.

How many Theravance Biopharma (TBPH) shares does Rhonda Farnum hold after this Form 4?

After the reported grant, Rhonda Farnum directly holds 251,449 Ordinary Shares of Theravance Biopharma. This total includes the newly awarded 18,750 shares and represents her direct equity stake reported in the filing, giving investors a clearer view of her current share ownership.

Was the Theravance Biopharma (TBPH) insider transaction a market buy or sell?

The transaction was not a market buy or sell; it was a grant. The Form 4 uses code “A” described as “Grant, award, or other acquisition,” with a price of $0.00 per share, indicating compensation-based share issuance rather than an open-market transaction.

What is the significance of transaction code “A” in the Theravance Biopharma (TBPH) Form 4?

Transaction code “A” in this Form 4 denotes a “Grant, award, or other acquisition” of shares. For Rhonda Farnum, it signals she received 18,750 Ordinary Shares as an equity award, increasing her holdings without buying shares on the open market.

Does the Theravance Biopharma (TBPH) Form 4 show any insider share sales by Rhonda Farnum?

The Form 4 does not show any insider share sales by Rhonda Farnum. It reports only one acquisition transaction via a share grant, with zero transactions classified as sales, gifts, tax withholdings, or derivative exercises in the transaction summary.